Publication Author: Sullivan_Sean

• Comparison of hospitalization rates in patients with community-acquired pneumonia treated with telithromycin for 5 or 7 days or clarithromycin for 10 days.

  Tellier G, Chang JR, Asche CV, Lavin B, Stewart J, Sullivan SD. Comparison of hospitalization rates in patients with community-acquired pneumonia treated with telithromycin for 5 or 7 days or clarithromycin for 10 days. Curr Med Res Opin. 2004 May;20(5):7

  rakerr2

  May 1, 2004

• A computer simulation model of the natural history and economic impact of chronic obstructive pulmonary disease.

  Borg S, Ericsson A, Wedzicha J, Gulsvik A, Lundbäck B, Donaldson GC, Sullivan SD. A computer simulation model of the natural history and economic impact of chronic obstructive pulmonary disease. Value Health. 2004 Mar-Apr;7(2):153-67.

  rakerr2

  March 1, 2004

• Randomized trial of pharmacist interventions to improve depression care and outcomes in primary care.

  Capoccia KL, Boudreau DM, Blough DK, Ellsworth AJ, Clark DR, Stevens NG, Katon WJ, Sullivan SD. Randomized trial of pharmacist interventions to improve depression care and outcomes in primary care. Am J Health Syst Pharm. 2004 Feb 15;61(4):364-72.

  rakerr2

  February 15, 2004

• Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C.

  Sullivan SD, Craxi A, Alberti A, Giuliani G, De Carli C, Wintfeld N, Patel KK, Green J. Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C. Pharm

  rakerr2

  January 1, 2004

• A cost-effectiveness analysis of fondaparinux sodium compared with enoxaparin sodium as prophylaxis against venous thromboembolism: use in patients undergoing major orthopaedic surgery.

  Sullivan SD, Davidson BL, Kahn SR, Muntz JE, Oster G, Raskob G. A cost-effectiveness analysis of fondaparinux sodium compared with enoxaparin sodium as prophylaxis against venous thromboembolism: use in patients undergoing major orthopaedic surgery. Pharm

  rakerr2

  January 1, 2004

• Clinical use of medical devices in the ‘Bermuda Triangle’.

  Kessler L, Ramsey SD, Tunis S, Sullivan SD. Clinical use of medical devices in the ‘Bermuda Triangle’. Health Aff (Millwood). 2004 Jan-Feb;23(1):200-7.

  rakerr2

  January 1, 2004

• Quality of life in adolescents with mild asthma.

  Hallstrand TS, Curtis JR, Aitken ML, Sullivan SD. Quality of life in adolescents with mild asthma. Pediatr Pulmonol. 2003 Dec;36(6):536-43.

  rakerr2

  December 1, 2003

• Cost-effectiveness analysis of early intervention with budesonide in mild persistent asthma.

  Sullivan SD, Buxton M, Andersson LF, Lamm CJ, Liljas B, Chen YZ, Pauwels RA, Weiss KB. Cost-effectiveness analysis of early intervention with budesonide in mild persistent asthma. J Allergy Clin Immunol. 2003 Dec;112(6):1229-36.

  rakerr2

  December 1, 2003

• The economics of venous thromboembolism prophylaxis: a primer for clinicians.

  Davidson BL, Sullivan SD, Kahn SR, Borris L, Bossuyt P, Raskob G. The economics of venous thromboembolism prophylaxis: a primer for clinicians. Chest. 2003 Dec;124(6 Suppl):393S-396S. Review.

  rakerr2

  December 1, 2003

• Vascular catheter site care: the clinical and economic benefits of chlorhexidine gluconate compared with povidone iodine.

  Chaiyakunapruk N, Veenstra DL, Lipsky BA, Sullivan SD, Saint S. Vascular catheter site care: the clinical and economic benefits of chlorhexidine gluconate compared with povidone iodine. Clin Infect Dis. 2003 Sep 15;37(6):764-71. Epub 2003 Aug 27.

  rakerr2

  September 15, 2003